Eyepoint Pharmac Stock Price, News & Analysis

EyePoint Pharmaceuticals (Nasdaq: EYPT) granted non-statutory stock options as inducement awards under NASDAQ Listing Rule 5635(c)(4) to seven new employees totaling 31,000 shares.

The options were granted on November 14, 2025, carry an exercise price of $11.58 (closing price that day), have a 10-year term, and vest over four years with 25% vesting at the first anniversary and the remainder monthly over three years, subject to continued service.

EyePoint (Nasdaq: EYPT) reported Q3 2025 results and corporate updates on Nov 5, 2025. Key operational items include completed enrollment of Phase 3 LUGANO and LUCIA for DURAVYU in wet AMD with >900 patients randomized and readouts beginning mid-2026, and initiation of a pivotal Phase 3 DME program (COMO and CAPRI) with first dosing expected Q1 2026 and FDA alignment on a non-inferiority approval pathway.

Preclinical data show DURAVYU reduces IL-6 activity >50% via JAK-1 inhibition plus VEGF receptor blockade. A $172.5 million underwritten offering in October fully funds the DME program and, with existing cash, extends runway into Q4 2027.

Q3 financials: revenue $1.0M versus $10.5M year-ago, operating expenses $63.0M, net loss $59.7M, and cash/securities $204M as of Sept 30, 2025 (plus ~$162M net October proceeds).

EyePoint Pharmaceuticals (NASDAQ: EYPT) announced management will participate in three investor events in November 2025: a Guggenheim Healthcare Innovation fireside chat on Nov 10, 2025 at 10:30 a.m. ET, a Stifel 2025 Healthcare corporate presentation on Nov 12, 2025 at 10:40 a.m. ET, and Jefferies London investor 1x1 meetings on Nov 17, 2025.

A live webcast and archived replay of each presentation will be available via the Investors section of the company website at www.eyepointpharma.com.

EyePoint (NASDAQ: EYPT) will report its third quarter 2025 financial results on November 5, 2025 and will host a conference call and live webcast at 8:30 a.m. ET.

Investors can register for the live audio conference via the provided audio conference link and access a live audio webcast and replay through the company's Investors section at www.eyepointpharma.com.

EyePoint (NASDAQ: EYPT) granted inducement non‑statutory stock options to three new employees to purchase an aggregate of 13,500 shares, effective October 15, 2025, in accordance with NASDAQ Listing Rule 5635(c)(4).

The options carry an exercise price of $11.73 (closing price on October 15, 2025), a 10‑year term, and vest over four years (25% after one year, then monthly over three years), subject to continued service. Grants were approved by the Compensation Committee as inducements for new hires.

EyePoint (NASDAQ: EYPT) priced an underwritten public offering on Oct 14, 2025 of 11,000,000 common shares at $12.00 per share and pre-funded warrants to purchase up to 1,500,000 shares at $11.999 each.

The aggregate gross proceeds are expected to be approximately $150 million before underwriting discounts, with closing expected on or about Oct 16, 2025. EyePoint granted underwriters a 30-day option to purchase up to an additional 1,875,000 shares. Net proceeds are intended to fund clinical development of DURAVYU for wet AMD and DME, earlier-stage pipeline work, and general corporate purposes.

EyePoint Pharmaceuticals (NASDAQ: EYPT) announced a proposed underwritten public offering of $150.0 million of common stock with a 30‑day underwriter option to purchase up to an additional $22.5 million. The company said proceeds are intended to advance clinical development of DURAVYU for wet AMD and DME, support earlier‑stage pipeline programs, and for general corporate purposes. J.P. Morgan, Jefferies, Citigroup, and Guggenheim are joint book‑running managers. The offering is subject to market conditions and will be made via a prospectus supplement to an effective Form S‑3 registration statement.

EyePoint (Nasdaq: EYPT) announced initiation of pivotal Phase 3 trials for DURAVYU (vorolanib intravitreal insert) in diabetic macular edema (DME), with first patient dosing anticipated in Q1 2026. The FDA-aligned program comprises two identical non-inferiority trials (COMO and CAPRI), each enrolling approximately 240 patients and comparing DURAVYU 2.7mg to on-label aflibercept 2mg, with redosing every six months.

Primary endpoint is change in BCVA blended at weeks 52 and 56. New preclinical data show vorolanib inhibits VEGFRs and JAK receptors, reducing IL-6 activity by >50% in vitro and supporting prior Phase 2 VERONA six-month efficacy signals and sustained six-month delivery from a single dose.

EyePoint Pharmaceuticals (Nasdaq: EYPT), a retinal disease therapeutics company, has granted inducement stock options to eight new employees outside of its 2023 Long-Term Incentive Plan. The grants, approved on September 15, 2025, include options to purchase up to 140,600 shares at an exercise price of $13.41 per share.

The options have a ten-year term and follow a four-year vesting schedule, with 25% vesting after the first year and the remainder vesting monthly over three years, contingent on continued employment.